Vanda Pharmaceuticals criticized a legislative proposal in the FDA's FY 2027 budget that would remove the 180-day statutory deadline for new drug application reviews, replacing it with longer timelines under PDUFA and GDUFA goals. This change could extend review times to 10-12 months, delaying patient access to new medicines and increasing uncertainty for small innovators. The proposal also seeks to replace formal evidentiary hearings on drug non-approvals with a weaker internal appeal process, despite recent court rulings requiring such hearings. Vanda urges the FDA and Congress to reject this proposal, warning it entrenches bureaucratic delays and reduces transparency.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
QuickLogic and PQSecure Technologies demonstrated that PQSecure's CRYSTAL-1000C post-quantum cryptographic IP can be efficiently implemented on QuickLogic's reprogrammable eFPGA fabric within SoCs. This allows field-upgradeable security without costl...
Relmada Therapeutics, a clinical-stage biotech company focused on oncology and CNS therapies, will announce its financial results for Q2 2026 on August 6, 2026. The company will host a conference call and webcast to discuss the results and recent bus...
Gilat Satellite Networks Ltd., a global leader in satellite networking technology, will release its second quarter 2026 financial results on August 5, 2026. Following the release, CEO Adi Sfadia and CFO Gil Benyamini will hold a conference call and w...
B&M European Value Retail's first-quarter update has divided analysts, with Deutsche Bank upgrading the stock to 'hold' citing stabilizing profit margins and a sensible turnaround strategy by new CEO Tjeerd Jegen. Deutsche Bank raised its profit fore...
